Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 24
- Registration Number
- NCT00000896
- Locations
- ๐บ๐ธ
Ucsd, Avrc Crs, San Diego, California, United States
๐บ๐ธUniversity of Colorado Hospital CRS, Aurora, Colorado, United States
๐บ๐ธIndiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 18
- Registration Number
- NCT00000689
- Locations
- ๐บ๐ธ
USC CRS, Los Angeles, California, United States
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 36
- Registration Number
- NCT00001090
- Locations
- ๐บ๐ธ
UAB AVEG, Birmingham, Alabama, United States
๐บ๐ธUniv. of Rochester AVEG, Rochester, New York, United States
๐บ๐ธJHU AVEG, Baltimore, Maryland, United States
The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 50
- Registration Number
- NCT00000989
- Locations
- ๐บ๐ธ
UCLA CARE Center CRS, Los Angeles, California, United States
๐บ๐ธBeth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Ctr., New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.